The Advisory Board (AB) provides strategic guidance and direction for Biological Dynamics' R&D and commercial operations. The AB is comprised of industry leaders who have made significant contributions to advancing the field of genomics, nanotechnology, oncology, and clinical practice.
Mark J. Adler, MD - Chairman
As a board-certified oncologist, a recipient of the NIH Physician-Scientist Award and Internist, Dr. Adler supports Biological Dynamics with a blend of clinical, corporate, and strategic perspectives.
Dr. Adler founded and led San Diego Cancer Center for over 20 years. Under his leadership, the Center participated in numerous clinical drug trials, developing a national reputation for clinical excellence (Hope Award). Dr. Adler served as on-site PI for multi-center phase II and III studies; he is currently a co-investigator with the J. Craig Venter Institute for its flagship genomic-based clinical trial and continues to publish on developments at the vanguard of oncology.
Presently a member of WebMD's Board of Directors, Dr. Adler continues to pursue his passion for genomics and molecular biology as Director of the San Diego Cancer Research Institute.
Eric Topol, MD
Dr. Topol is internationally renowned for his work on the frontier of medicine, particularly at the intersection of cardiology, genetics, and digital medicine.
He is a practicing cardiologist at Scripps in La Jolla, California, and is widely credited for the Cleveland Clinic's status as the leading center for heart care. One of the top 10 most-cited researchers in medicine, Dr. Topol has published 1100 peer-reviewed articles and over 30 medical textbooks. His research has earned him the title "Doctor of the Decade" from Thomson Reuter's Institute for Scientific Information. He is highly published in the NY Times, Wall Street Journal, and is an editor of Medscape.
Dr. Topol is also the Director of the Scripps Translational Science Institute in La Jolla, California.
Dennis Carson, MD
Internationally recognized immunologist and cancer biologist, Dr. Carson has the distinction of being one of the few living oncologists to formulate a cure for a disease. For Dr. Carson, this came in the form of the drug Leustatin- which cures the previously uniformly fatal Hairy Cell Leukemia. His interest in the treatment of non-proliferative disorders led him to Biological Dynamics, particularly the company's innovative approach for evaluating treatment response in blood cancers.
Dr. Carson is a founder of Vical, Inc. (DNA vaccines), Dynavax Technologies (CpG TLR9 therapeutics), Triangle Pharmaceuticals (acquired by Gilead for $464M in 2003), Salmedix (acquired in 2005 by Cephalon for $200M), Wintherix (WNT pathway cancer therapeutics), and TeLoRmedix (targeted immunotherapeutics). He was elected to Membership in both the National Academy of Sciences and the National Institute of Medicine.
Dr. Carson received his Bachelor's degree from Haverford, his M.D. from Columbia, and had postdoctoral training at the Salk Institute.
Michael Heller, PhD
In addition to being a renowned expert in nanotechnology and a UCSD professor of Bioengineering and Nanoengineering, Dr. Heller has been successful in fostering four companies and hundreds of students. As a mentor for Biological Dynamics' CEO, Raj Krishnan, he was instrumental in bringing ACE technology from its original concept to what it is today.
Dr. Heller continues to push the cutting edge of medical diagnostics in multiple areas, the most significant of these being serum markers for TBI. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample-to-answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage, and fluorescent energy transfer in DNA.
Dave S. B. Hoon M.Sc, Ph.D
As Professor and Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon has unparalleled experience in the translational research of innovative technologies. As one of world's leading experts on circulating cfDNA, he provides the Biological Dynamics team with guidance in their pursuit of meaningful clinical applications of ACE technology.
He has coauthored more than 330 peer-reviewed articles and reviews, primarily related to the translational molecular oncology of human solid tumors, and has over 25 patents on his studies. As Founding Director of the Department of Molecular Oncology, Dr. Hoon continues to pioneer investigations of RNA/genomic/epigenomic biomarkers for diagnostic, prognostic, and predictive assessment of residual tumor cells. Dr. Hoon spearheads investigations of circulating DNA/miRNA biomarkers for staging cancer and classification of solid tumors, including melanoma, breast cancer, gastrointestinal cancer, and primary brain tumors.
Scott M. Lippman, MD
Scott M. Lippman, MD, is a Director of the UCSD Moores Cancer Center, a Professor of Medicine at the UCSD School of Medicine, and an adjunct professor at several institutions including the Salk Institute, the Sanford-Burnham Medical Research Institute, and the MD Anderson Cancer Center. His 25+ years of experience as PI, plus his ability to build high-caliber clinical teams, as well as his established reputation with patients, students, and Federal agencies alike make him uniquely qualified to advise young growing companies.
Dr. Lippman has authored more than 300 publications in journals, including The New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Sciences and The Lancet. He received his medical degree from The Johns Hopkins University School of Medicine and he is board-certified in internal medicine, hematology, and medical oncology.
John Watson, PhD
Dr. Watson is a Founder of the William von Liebig Center for Entrepreneurship and Technology Advancement, as well as a Professor of Bioengineering at the UC San Diego. Prior to joining UCSD, he worked over 27 years at National Institutes of Health (NIH), most recently as Director of Clinical and Molecular Medicine at the National Heart, Lung, and Blood Institute, where he oversaw over 60 major clinical trials involving thousands of patients and all the engineering in cardiovascular medicine programs such as assisted circulation for advanced heart failure, less invasive diagnostic imaging, and implantable biomaterials.
Dr. Watson is one of the top experts on a coordinated approach to translating research- an approach that addresses clinical, regulatory, and payer aspects simultaneously, shortening time-to-market for medical innovations. His work on the conception, design, development, and clinical trial of left ventricular assist devices and the artificial heart contributed to the federal regulatory and payment decision-making process.
In 1998, he was inducted into the National Academy of Engineering (NAE), becoming the first member so recognized from the NIH. He was an invited member of the Nominating Committee for the Nobel Prize, the Japanese Kyoto Prize, and the NAE Draper Prize. Dr. Watson holds a PhD in physiology from the University of Texas Southwestern Medical School (1972) and engineering degrees from University of Cincinnati and Southern Methodist University.